Trial Profile
A prospective randomized controlled trial of Apatinib or S-1 or Capecitabine as Maintence Trerapy after surgery of tumors of the biliary tract
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Apr 2018
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 16 Apr 2018 New trial record